The humanised monoclonal antibody Herceptin[registered] targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30 per cent of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin[registered] have clearly.
download Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) pdf free
Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) pdf download
D. Khayat ebooks downloads
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.